List of Excipients in Branded Drug AZACITIDINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	AZACITIDINE	azacitidine	0781-3253	MANNITOL
Sandoz Inc	AZACITIDINE	azacitidine	0781-9253	MANNITOL
BluePoint Laboratories	AZACITIDINE	azacitidine	68001-313	SODIUM PHOSPHATE, DIBASIC, DIHYDRATE
BluePoint Laboratories	AZACITIDINE	azacitidine	68001-313	SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

Generic Drugs Containing AZACITIDINE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	azacitidine	0143-9606	MANNITOL
NorthStar RxLLC	azacitidine	16714-578	MANNITOL
NorthStar RxLLC	azacitidine	16714-927	MANNITOL
Accord Healthcare Inc	azacitidine	16729-306	MANNITOL

What are the Most Frequently-Used Excipients in AZACITIDINE?

# Of NDCs	Excipient
30	MANNITOL

Azacitidine Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Azacitidine has two commercial formulation platforms: the injectable suspension Vidaza and the oral tablet Onureg. The main formulation problem is chemical instability in aqueous media, while the main commercial opportunity is improving room-temperature stability, reconstitution, administration convenience, and oral product economics. Generic injectable entry is mature; the stronger opportunities are differentiated oral products, ready-to-use parenteral presentations, improved packaging, and excipient-enabled manufacturing platforms.

What formulations contain azacitidine?

Azacitidine is a cytidine nucleoside analogue used in myelodysplastic syndromes and acute myeloid leukemia. It is marketed in the United States as:

Product	Dosage form	Strength	Administration	Primary formulation issue
Vidaza	Lyophilized powder for injectable suspension	100 mg vial	Subcutaneous or intravenous	Aqueous instability, reconstitution burden, short in-use stability
Onureg	Film-coated oral tablet	200 mg and 300 mg	Once daily on Days 1-14 of a 28-day cycle	Moisture sensitivity, gastrointestinal exposure, absorption variability

Vidaza contains azacitidine and mannitol in a sterile lyophilized formulation. The product is reconstituted with sterile water before administration. The label imposes handling and storage controls because reconstituted azacitidine has limited stability and must be used within specified time limits depending on storage conditions (U.S. Food and Drug Administration [FDA], 2023a).

Onureg is an oral, film-coated tablet containing azacitidine with conventional tablet excipients. The oral product does not use the same administration model as Vidaza. Onureg is approved for continued treatment of adult patients with acute myeloid leukemia who achieved complete remission or complete remission with incomplete blood count recovery after intensive induction chemotherapy and cannot complete intensive curative therapy (FDA, 2023b).

Which excipient problems create the largest commercial opportunities?

The highest-value opportunities relate to stability and product handling rather than simple tablet compression.

Aqueous instability

Azacitidine undergoes hydrolytic degradation in aqueous media. The degradation profile is affected by pH, temperature, concentration, light exposure, and contact time. A formulation that extends reconstituted stability could reduce pharmacy waste and simplify hospital administration.

Potential approaches include:

• pH-controlled aqueous systems
• dry suspensions that require less manipulation
• lyophilized cakes with improved reconstitution
• co-lyophilized stabilizing excipients
• sterile powder systems with lower residual moisture
• dual-chamber containers that separate diluent from drug
• ready-to-use presentations with validated refrigerated stability

The main technical constraint is that excipient selection cannot improve physical handling at the cost of accelerating azacitidine degradation. Each candidate requires degradation-product profiling rather than reliance on assay alone.

Reconstitution and administration burden

Vidaza requires pharmacy preparation, aseptic handling, and administration within a defined period. This creates opportunities for:

• prefilled syringes
• dual-chamber syringes
• ready-to-use suspensions
• smaller-volume reconstitution
• closed-system transfer devices
• vial systems with improved powder wetting
• formulations compatible with automated compounding

These products could compete on total cost of treatment even if the active ingredient price is similar. Hospital purchasing decisions often consider preparation time, nursing time, waste, hazardous-drug handling, and medication-error risk.

Moisture and packaging sensitivity

Oral azacitidine tablets require control of moisture uptake during manufacture and storage. Excipients, film coatings, bottle systems, desiccants, and blister materials must be selected as an integrated package.

Commercially relevant options include:

• high-barrier aluminum-aluminum blisters
• multilayer high-density polyethylene bottles
• desiccant-integrated closures
• low-moisture excipient grades
• moisture-protective film coatings
• nitrogen-purged packaging
• unit-dose blister presentations for oncology clinics

Packaging can become an important part of the product differentiation strategy if the active pharmaceutical ingredient is already available from multiple suppliers.

What excipients are suitable for injectable azacitidine?

The injectable platform requires excipients with strong regulatory precedent, low particulate risk, and compatibility with sterile manufacturing.

Mannitol

Mannitol is the established bulking agent in Vidaza. It supports cake formation during lyophilization and provides a familiar excipient profile for injectable products. Its use reduces regulatory novelty but does not by itself solve aqueous instability after reconstitution.

Mannitol remains a logical starting point for generic and follow-on injectable products because it has:

• established parenteral use
• broad supplier availability
• a well-understood lyophilization profile
• relatively low formulation complexity
• a clear precedent in the reference product

Phosphate buffering

Phosphate salts can control pH, but buffering must be optimized against chemical degradation and precipitation risk. A stronger buffer is not automatically preferable. The formulation target is the pH range that minimizes total degradation while preserving suspension characteristics and injectability.

A phosphate system also requires assessment of:

• freeze-concentration effects during lyophilization
• cake collapse
• reconstitution time
• osmolality
• compatibility with container closure components
• visible and subvisible particles

Surfactants and wetting agents

A surfactant may improve wetting and reconstitution of the lyophilized cake, but it can introduce oxidation, adsorption, foaming, and particulate concerns. Polysorbates are common in biologics but are not automatically optimal for a small-molecule cytotoxic product.

Candidate surfactants should be screened for:

• compatibility with azacitidine
• peroxide content
• extractables and leachables
• syringeability
• foam formation
• impact on suspension uniformity

Polyols and alternative bulking agents

Sucrose, trehalose, lactose, and other polyols may improve cake structure or protect the active during freezing and drying. Their commercial value depends on whether they deliver a measurable improvement over mannitol.

Trehalose and sucrose can increase amorphous matrix formation but may raise concerns about residual moisture, collapse temperature, and reconstitution behavior. Lactose may create compatibility or reducing-sugar concerns. These excipients are better suited to differentiated formulation development than to a low-risk generic strategy.

What excipients are suitable for oral azacitidine?

Oral azacitidine requires a balance between manufacturability, moisture control, rapid and reproducible dissolution, and protection from degradation.

Core tablet excipients

A conventional formulation can use:

• microcrystalline cellulose for filler and dry binding
• mannitol for dilution and mouthfeel
• croscarmellose sodium for disintegration
• colloidal silicon dioxide for flow improvement
• sodium stearyl fumarate or another low-lubrication excipient
• a protective film-coating system

The reference product provides a regulatory benchmark, but copying the excipient composition does not guarantee equivalent performance. Particle size, granulation method, compression force, lubricant distribution, and coating weight can change dissolution and stability.

Moisture-control strategy

The oral formulation should be developed with a target water activity rather than only a total moisture specification. Excess water may accelerate degradation or alter tablet mechanical properties. Too little moisture may increase friability or impair compression.

The development program should assess:

• sorption isotherms
• water activity
• tablet hardness and friability
• dissolution after accelerated storage
• impurity growth
• packaging ingress
• stability after repeated opening
• compatibility with desiccants

A protective film coating can reduce moisture transfer, but the coating must not slow dissolution beyond the clinically relevant profile.

Modified-release opportunities

The current oral product is an immediate-release tablet. Modified-release products could attempt to reduce gastrointestinal exposure peaks, change dosing frequency, or improve tolerability. The commercial value is uncertain because azacitidine exposure is linked to both efficacy and toxicity, and a modified-release product may require new clinical evidence.

Potential concepts include:

• delayed-release tablets
• gastro-resistant systems
• multiparticulate capsules
• pulsatile dosing
• extended-release matrices
• enteric-coated pellets

These technologies have a higher regulatory and clinical burden than a conventional immediate-release generic. Their strongest commercial rationale would be a demonstrated improvement in adherence, gastrointestinal tolerability, or outpatient treatment persistence.

What patent and regulatory rights protect azacitidine products?

Azacitidine is an established small molecule, so it does not carry biosimilar risk. The relevant competition is from generic injectable products, oral generic products, 505(b)(2) formulations, and authorized or licensed versions.

Vidaza patent and exclusivity position

Vidaza received FDA approval on May 19, 2004, for myelodysplastic syndromes. Its market protection was historically based on orphan-drug exclusivity, regulatory protections, and formulation or method-of-use rights rather than continuing composition-of-matter protection for azacitidine itself (FDA, 2023a).

The injectable market has been exposed to generic competition. The commercial barriers now center on:

• sterile manufacturing capacity
• cytotoxic handling controls
• formulation equivalence
• reconstitution stability
• injectable product quality
• hospital contracting

Onureg patent and exclusivity position

Onureg was approved on September 1, 2020. The product benefits from a more recent formulation and method-of-use patent estate than Vidaza. Relevant rights may cover oral dosage forms, dosing schedules, treatment of specific patient populations, pharmaceutical compositions, and manufacturing processes.

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity in the United States. Patent status can differ by jurisdiction, and listed patent expiry dates do not necessarily establish the date of commercial generic launch because Paragraph IV litigation, settlements, pediatric extensions, and regulatory exclusivity can affect timing (FDA, 2024).

Paragraph IV and generic-entry risk

A generic applicant may challenge listed patents through an abbreviated new drug application and Paragraph IV certification. The principal attack points are likely to include:

• obviousness of the oral composition
• lack of written description or enablement
• anticipation by prior oral azacitidine formulations
• non-infringement based on excipient differences
• invalidity of dosing or patient-selection claims
• lack of clinical relevance for formulation limitations

A formulation patent is stronger when the claims connect a defined excipient system to a demonstrated stability or bioavailability result. Broad claims covering routine tablet excipients are more vulnerable to obviousness challenges.

How strong is the azacitidine patent estate?

The patent estate is stronger for oral maintenance therapy than for the legacy injectable product, but its strength depends on claim scope and enforceability.

Asset area	Relative strength	Main vulnerability
Azacitidine active ingredient	Low	Old, established molecule
Lyophilized injectable formulation	Moderate	Prior art and generic formulation work
Oral tablet composition	Moderate to strong	Obviousness and non-infringement arguments
Oral dosing regimen	Moderate	Method-of-use validity and label carve-outs
Oncology patient population	Moderate	Treatment-label limitations
Manufacturing process	Variable	Design-around through process changes
Packaging and stability	Moderate	Difficulty proving infringement and claim scope

A company developing an oral follow-on should design around specific composition claims while preserving bioequivalence. A company developing a differentiated product should pursue claims based on measurable performance, such as improved stability, reduced degradation, controlled release, or a defined exposure profile.

What commercial opportunities exist for azacitidine excipients?

Generic injectable azacitidine

The injectable product offers the lowest clinical risk but has intense price competition. Commercial opportunity depends on manufacturing economics and hospital distribution rather than excipient novelty.

Potential advantages include:

• lower reconstitution waste
• longer in-use stability
• reduced preparation time
• better vial utilization
• simplified cold-chain requirements
• ready-to-use administration

A generic that only matches the reference product may have limited margin unless it has a reliable supply chain and competitive contracting strategy.

Differentiated injectable products

A ready-to-use or extended-stability injectable could support a 505(b)(2) strategy if it provides a clinically or operationally meaningful difference. The main value proposition would be hospital workflow improvement.

High-value product concepts include:

1. A dual-chamber syringe that keeps azacitidine dry until administration.
2. A ready-to-use suspension with extended refrigerated stability.
3. A lower-volume formulation that reduces administration time.
4. A formulation that reduces vial waste for dose-band use.
5. A container system compatible with automated oncology compounding.

Oral generic azacitidine

An oral generic may address a substantial market but faces formulation, bioequivalence, patent, and commercial hurdles. The most attractive strategy is a conventional immediate-release tablet with:

• robust moisture protection
• reliable dissolution across pH conditions
• scalable direct compression or dry granulation
• packaging that supports oncology dispensing
• low tablet burden
• stable supply of high-quality azacitidine API

Oral differentiated products

A differentiated oral product could target adherence, tolerability, or dosing flexibility. Candidate approaches include:

• smaller tablets
• orally disintegrating tablets
• multiparticulates for dose flexibility
• modified-release systems
• fixed-dose packaging for 28-day cycles
• calendar blister packs
• combination packaging with supportive-care medicines

Any product that changes systemic exposure or dosing frequency may require clinical development beyond a standard bioequivalence program.

How does azacitidine compare with decitabine?

Azacitidine and decitabine compete in the hypomethylating-agent market, but their formulation opportunities differ.

Attribute	Azacitidine	Decitabine
Injectable product	Vidaza	Dacogen and generic products
Oral product	Onureg	Oral decitabine/cedazuridine product marketed as Inqovi
Main injectable issue	Reconstitution and aqueous instability	Stability and sterile handling
Oral strategy	Conventional azacitidine tablet	Oral decitabine combined with cedazuridine to inhibit metabolism
Commercial differentiation	Formulation stability, convenience, dosing platform	Enzyme-inhibition strategy and oral exposure
Biosimilar risk	None	None

Inqovi uses cedazuridine to inhibit cytidine deaminase and increase oral decitabine exposure. This creates a higher barrier to simple excipient-only competition because the product’s value depends on pharmacology, not only tablet design (FDA, 2021).

Azacitidine competitors can pursue excipient improvements without adding a second active ingredient, but the achievable improvement may be smaller than the pharmacokinetic advantage created by enzyme inhibition.

What manufacturing and intellectual-property barriers matter most?

The principal barriers are:

• control of azacitidine degradation products
• sterile processing for injectable products
• cytotoxic containment
• low-moisture tablet manufacturing
• high-quality API sourcing
• validated packaging
• bioequivalence under variable gastrointestinal conditions
• patent design-around
• oncology-channel contracting

For injectables, manufacturing know-how can be more important than excipient exclusivity. For oral products, the combination of formulation composition, process parameters, packaging, and clinical performance creates the more defensible position.

What is the likely generic launch scenario?

The most probable sequence is:

1. Continued price pressure in generic injectable azacitidine.
2. Additional oral generic activity after resolution or expiry of relevant Onureg protections.
3. Selective development of 505(b)(2) products with improved stability or administration.
4. Limited commercial success for modified-release products unless they show a clear clinical benefit.
5. Greater value for packaging and workflow improvements in hospital oncology settings.

A basic injectable generic can launch with limited differentiation. A ready-to-use injectable or improved oral product has greater commercial potential but requires more extensive development, regulatory support, and intellectual-property planning.

Key Takeaways

• Azacitidine has two distinct formulation markets: injectable Vidaza and oral Onureg.
• The core technical problem is aqueous and moisture-related instability.
• Mannitol provides the principal established lyophilization precedent for injectable azacitidine.
• Oral formulation opportunities center on moisture control, dissolution consistency, packaging, and dose convenience.
• Injectable generic competition is mature and price-sensitive.
• The strongest commercial opportunities are ready-to-use injectables, extended in-use stability, improved packaging, and differentiated oral delivery.
• Azacitidine has no biosimilar risk because it is a small molecule.
• Onureg has a more relevant formulation and method-of-use patent estate than legacy injectable azacitidine.
• A conventional oral generic is more commercially realistic than a modified-release product, but it remains exposed to patent and bioequivalence risk.
• Excipient innovation is most defensible when linked to measurable stability, bioavailability, handling, or adherence improvements.

FAQs

Can azacitidine be formulated as a ready-to-use injection?

Yes. A ready-to-use suspension, dual-chamber system, or other separated-component presentation is technically plausible. The main development requirements are chemical stability, sterility, uniformity, syringeability, particulate control, and validated container compatibility.

Which excipient is most important in injectable azacitidine?

Mannitol is the key established bulking agent in the Vidaza lyophilized product. The most important performance variables are not limited to the bulking agent and include pH control, residual moisture, cake structure, reconstitution time, and in-use stability.

Is oral azacitidine a good target for a 505(b)(2) product?

It can be, particularly where the product provides a defined advantage in stability, dosing convenience, absorption, or tolerability. A conventional tablet that only changes excipients may be better suited to an ANDA strategy if it meets bioequivalence and patent requirements.

Does azacitidine require biosimilar development?

No. Azacitidine is a chemically synthesized small molecule. Follow-on products generally use generic-drug or 505(b)(2) pathways rather than the biosimilar pathway.

What packaging offers the best opportunity for oral azacitidine?

High-barrier unit-dose packaging, including aluminum-based blister systems with moisture protection, offers the strongest starting point. The appropriate system depends on water activity, degradation kinetics, shelf-life targets, and repeated-opening stability.

References

1. U.S. Food and Drug Administration. (2021). INQOVI (decitabine and cedazuridine) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023a). VIDAZA (azacitidine) for injection prescribing information. FDA.

3. U.S. Food and Drug Administration. (2023b). ONUREG (azacitidine) tablets prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.